More about profits than patients

Donald Trump on Saturday signed an executive order allowing expedited research into psychedelics as potential treatments for mental disorders. (Like his?) “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America,” the statement reads.
“Can I have some, please?” Trump joked to assembled guests in the Oval Office.
Would we notice any difference?
In no way should you believe that Trump signed this order out of concern for anyone’s mental health. It’s simply another business area that someone close to him feels is insufficiently commodified and exploited financially. And that someone whispered in Trump’s ear. Likely after making a large donation to Trump, an investment in his businesses, or a purchase of his crypto. Is Don Jr. invested yet?
Big pharma is all over it. A site called Biopharmdive reports:
At least half a dozen biotechnology companies working on psychedelics saw their stocks rise following an executive order from the White House meant to encourage the development of these drugs for mental health.
The order, issued Saturday, directs the head of the Food and Drug Administration to provide a new — and controversial — kind of voucher to “appropriate” psychedelic medicines that the FDA has classified as potential breakthroughs for serious conditions. That classification, as well as the “national priority vouchers,” are designed to significantly speed up the development and regulatory review of certain therapies.
This is more about profits than patients.
Not that there isn’t public and medical interest, Scientific American reports:
An estimated 15.4 million adults in the U.S. live with severe mental illness, according to the National Institutes of Health. Veterans are at particular risk: Research shows that suicide rates are nearly twice as high among veterans as they are in the general population. And existing drugs, such as selective serotonin reuptake inhibitors (SSRIs), that are designed to treat depression and other mental health conditions aren’t always effective or accessible for everyone. An increasingly vocal cadre of researchers believe psychedelic substances could offer more effective treatments. And in some clinical trials, psilocybin, MDMA and LSD have been found to have promising results in treating mental health conditions.
“We need better treatments,” says Alan Davis, director of the Center for Psychedelic Drug Research and Education at the Ohio State University. “We need to be able to help people, and I think psychedelic therapies will offer a new way in which to do that.”
But research into these drugs is slow and hard to do, not least because the U.S. government categorizes many psychedelics as Schedule I drugs, which means they are considered to be dangerous and to have a high potential for abuse and “no currently accepted medical use,” according to the definition in the Code of Federal Regulations. In most cases, the possession of such drugs is federally criminalized, and that adds significant hurdles for researchers who are trying to study their effects.
That’s part of the reason why very few therapies that use psychedelic drugs have been approved for use in the U.S. One of the most well studied psychedelics, MDMA, was set back in 2024 when, citing insufficient and flawed research, the Food and Drug Administration rejected a proposal to approve it as a treatment for post-traumatic stress disorder.
Maybe it’s a good thing. Half of this country appears deranged. We’ll all have PTSD before Trump and Trumpism are gone.










